B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

B of A Securities analyst Alec Stranahan has maintained a 'Buy' rating on Agios Pharmaceuticals (NASDAQ: AGIO) and raised the price target from $46 to $50. This adjustment reflects a positive outlook for the company's performance.